AMAG Pharmaceuticals
AMAG
AMAG was delisted on the 13th of November, 2020.
185 hedge funds and large institutions have $913M invested in AMAG Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 87 increasing their positions, 51 reducing their positions, and 43 closing their positions.
71% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 51
10% less funds holding
Funds holding: 206 → 185 (-21)
35% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 43
36% less capital invested
Capital invested by funds: $1.43B → $913M (-$516M)
97% less call options, than puts
Call options by funds: $4.87M | Put options by funds: $172M
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$119M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$26M |
| 3 |
State Street
Boston,
Massachusetts
|
+$25.9M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$14.8M |
| 5 |
PA
Perceptive Advisors
New York
|
+$12.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$59.1M |
| 2 |
CCM
Consonance Capital Management
New York
|
-$35.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$23.5M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$21.3M |
| 5 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
-$20.9M |
AMAG Hedge Fund Activity: Q1 2017 in Review
185 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in AMAG Pharmaceuticals (AMAG) for Q1 2017, worth a combined $913M — down 36% from $1.43B a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of AMAG and 28 opened new positions — a net loss of 15 holders — while 51 trimmed existing stakes and 87 added.
The largest buyer was BlackRock, adding an estimated $119M. The largest seller was Janus Henderson Investors US, cutting an estimated $59.1M.
- 185 institutional investors held AMAG Pharmaceuticals (AMAG) as of Q1 2017, down from 206 in Q4 2016.
- Funds reported $913M of AMAG Pharmaceuticals stock for Q1 2017, down 36% quarter-over-quarter.
- 28 funds opened new AMAG Pharmaceuticals positions in Q1 2017 and 43 closed out, a net change of -15 holders.
- The largest AMAG Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $119M added.
- The largest AMAG Pharmaceuticals seller in Q1 2017 was Janus Henderson Investors US, an estimated $59.1M sold.
Based on aggregated 13F filings for Q1 2017.